

Case Report

Neutralizing Antibodies to Botulinum Toxin Type A as a Secondary Treatment Failure: A Case Report from Mumbai, India

Narmada Matang Khatri, MBBS, DVD*

Neo Skin Aesthetics, Centre for Skin, Hair, Laser & Cosmetic Dermatology, Powai, Mumbai, India

*Corresponding author

Narmada Matang Khatri, MBBS, DVD

Dermatologist, Neo Skin Aesthetics, Centre for Skin, Hair, Laser & Cosmetic Dermatology, Powai, Mumbai, India; E-mail: ask@neoskinaesthetics.com

Article information

Received: January 17th, 2022; Revised: April 29th, 2022; Accepted: May 6th, 2022; Published: May 12th, 2022

Cite this article

Khatri NM. Neutralizing antibodies to botulinum toxin type A as a secondary treatment failure: An introductory case report from Mumbai, India. *Trichol Cosmetol Open J*. 2022; 5(1): 4-9. doi: [10.17140/TCOJ-5-117](https://doi.org/10.17140/TCOJ-5-117)

ABSTRACT

Botulinum toxin use in aesthetic medicine for treatment of facial rhytids is common and has become more and more popular in India in recent times. Botulinum toxin (BoNT) is produced by clostridium botulinum which is an anaerobic, spore forming, rod shaped bacteria. The botulinum toxin complex contains a 150 KD neurotoxin together with a complex additional protein. The neurotoxin is cleaved by the clostridial proteases into heavy and light chain. The heavy chain (100 KD) after cleavage binds to gangliosides and a protein receptor on the presynaptic nerve ending, whereas the light chain (50 KD) blocks the release of acetylcholine, leading to a dose dependent weakening of the target muscle.

Keywords

Botulinum neurotoxin type A; Neutralizing antibodies; Secondary treatment failure; Aesthetic treatment; Facial rhytides.

INTRODUCTION

There are the seven distinct serotypes of botulinum toxin A-G, of which A and B are used clinically. Various commercially available botulinum toxin type A (BoNT-A) commonly used in India are Incobotulinum-Xeomin®, Onabotulinum-Botox®, and Abobotulinum-Dysport®, respectively. Botulinum toxin was first used clinically in 1970s in ophthalmology to treat strabismus,¹ and over last two decades has gained widespread use in conditions requiring inhibition of excessive muscle spasm. Medical indication of BoNT include movement disorders like spasticity, cervical dystonia, urological disorders like overactive bladder, dermatology conditions like hyperhidrosis and cosmetic indications of facial rhytids. The indicated clinical conditions are chronic in nature, and BoNT effects do not last more than few months; patients need to be treated repeatedly. Over the last 20-years botulinum toxin has gained popularity especially for cosmetic and aesthetic indications. However, there some patients who stop responding to the BoNT-A injections due to a variety of reasons, including emergence of immunoresistance as a result of neutralizing antibodies (NAb).

Botulinum Toxin Structure and Function

BoNT is composed of core neurotoxin and associated non-toxic

accessory proteins called NAP. The core neurotoxin consists of a 150 kD precursor protein that contains a 100 kD heavy chain and a 50 kD light chain, linked with a disulphide bond.² BoNT binds to the glycoprotein receptors on the cholinergic nerve terminal membrane, here the native vesicle recycling mechanisms are used to facilitate endocytosis of the 50 kD light chain into the cytoplasm.^{3,4} The light chain cleaves the soluble N-ethylmaleimide sensitive factor attachment protein receptor (SNARE) proteins involved in eventual transport of acetylcholine (Ach) vesicles and their docking with the presynaptic membrane before releasing Ach into the synaptic cleft. Different serotypes of BoNT affect different SNARE proteins, synaptosomal-associated protein-25 (SNAP-25) is cleaved by BoNT-A, BoNT-C, and BoNT-E, and VAMP (synaptobrevin) is cleaved by BoNT-B, BoNT-D, and BoNT-F.^{3,5} The impaired Ach exocytosis interferes with synaptic neural transmission in striate muscles as well as cholinergically innervated structures e.i. smooth muscles or exocrine glands.⁵ The core neurotoxin is accompanied by NAPs, which is comprised of hemagglutinin (50 kD) and non-hemagglutinin proteins (130 kD), this associates with the core neurotoxin to help prevent degradation.^{6,7} Different BoNT types have different NAP compositions. The only product where all NAPs have been removed is Incobotulinumtoxin A.⁸ The core neurotoxin and NAP are mixed with excipients which vary

among the different brands, include albumin, sucrose, lactose, sodium chloride, and disodium succinate.^{5,9-13} The active neurotoxin dissociates completely from the complexing proteins on reconstitution. Therefore, complexing proteins do not influence the therapeutics effect of the core neurotoxin (Table 1).^{1,14}

Immunogenicity

The relevance of immunogenicity in aesthetics is debated, however many reports suggest it should be considered seriously.^{6-8,16-24} The immunogenic potential of BoNT-A products depends on multiple factors including their formulations, quantity of antigenic protein, accessory proteins, and treatment related like toxin dosage, frequency and earlier exposure to toxin.²⁵ Immunogenicity is described as proteins ability to induce an immune response, as a consequence, stimulate antibody formation.²⁶ Like any other non-human, foreign protein, commercial BoNT-A preparations can initiate immune reaction on injection, particularly when these injections have been repeated several times.^{27,28} It is important to define the terms primary non-responders and secondary non-responders.

Primary and Secondary Non-Responders

There are several studies which have reported that some patients have never responded to BoNT-A, they were categorized as primary non-responders. In series of 235 patients receiving BoNT-A for multiple indications 9.1% were thought to have primary resistance and 7.5% secondary resistance.²⁹ Primary resistance was defined as a less than 25% response from the first injection despite two or three consecutive injections of increasing dosages. Primary resistance however is a rare phenomenon in clinical populations.³⁰

Secondary non-response is characterized by initial benefit in symptoms after BoNT-A treatment followed by loss of response with subsequent injection at some point in time of series of injection treatment. These patients cannot be categorized as non-responders, they fall under the definition of secondary non-

responders wherein there is an absence of clinical response and absence of any adverse effects after at least two consecutive treatment visits. Immunogenicity due to presence of Nabs is not the only or main cause of secondary non-response. Poor or no response to BoNT-A is more frequently due to an insufficient dosage, inappropriate muscle selection, or improper injection technique.³¹ In a meta-analysis of 8525 patients reported in 61 studies, the prevalence of Nabs was 3.5% among clinically responding patients and 53.5% in patients with secondary non-response, but half of the patients with SNR did not have Nabs.³² There are various studies which have used different assays for Nabs, which accounts for the marked variability in the reported frequency of the Nabs and poor correlation between the presence of Nabs and clinical response.

Botulinum Toxin Antibodies

BoNT antibodies can be divided into Nabs, targeting the core neurotoxin binding at the heavy chain, and non-neutralizing antibodies, targeting the accessory protein which may be clinically irrelevant. Some antibodies have been found to have bind to the regions of light chain of BoNT-A.³³ Antibodies detected against BoNT are typically of IgG-type, are sero specific. Patients who do not respond to BoNT-A due to development of Nabs usually respond to BoNT-B. However, this switch of serotypes exposes them to a higher risk of developing resistance to alternate type of BoNT, which can be attributed to about 30% structural homology in the heavy chain of BoNT-A and BoNT-B.³⁴

Nabs can decrease over prolonged duration, one of the studies showed that the average duration between the detection of NAb and subsequent reversal to a NAb-negative status was about 30-months.³⁵ However, the immunologic response to the same BoNT serotype can be reactivated by repeat treatments.^{35,36} An increase in dosage up to four times can restore the therapeutic response in some patients with partial SNR associated with Nabs.³⁷ Alternative strategy to gain the clinical response in patients with

Table 1. Pharmaceutical, Biological and Clinical Properties of BoNT/A Products¹⁵

Botulinum Toxin type A	Onabotulinum	Abobotulinum	Incobotulinum
Brand name	Botox®, Vistabel®	Dysport®, Azzalure®	Xeomin®
Approved aesthetic indication	Galbellar rhytides, lateral canthal rhytides	Moderate to severe Galbellar rhytides	Moderate to severe Galbellar rhytides and lateral canthal rhytides
Presentation	Vacuum-dried powder for reconstitution	Freeze dried (Lyophilized) powder for reconstitution	Freeze dried (Lyophilized) powder for reconstitution
Isolation Process	Precipitation	Precipitation and chromatography	Precipitation and chromatography
Composition	Clostridium botulinum toxin type A: HA and non-HA proteins	Clostridium botulinum toxin type A: HA and non-HA proteins	Clostridium botulinum toxin type A
Excipients*	100 U vial HSA 0.5 mg; NaCl 0.9 mg	500 U vial HSA 125 µg; Lactose 2.5 mg	100 U vial; HSA 1mg; Sucrose 4.6 mg
Molecular weight	900(150)	Not published (150)	150
Total Protein content ng per 100I U	5.0	4.87	0.44
Neurotoxin protein load (ngneurotoxin per 100 U*)	0.73	0.65	0.44
Neurotoxin potency U/ng	137	154	227
Shelf life	2-8 °C 2-3-years**	2-8 °C 2-years	Room Temp 3-4-years**
Storage after reconstitution	2-8 °C 24 hrs	2-8 °C 4 hrs	2-8 °C 24 hrs

*Units of measurements for three commercially available BoNT/A preparations are proprietary to each manufacturer and are not interchangeable.
**Depending on the number of units

SNR is to transition them to the formulation of BoNT that lacks the complexing proteins and hence have potentially lower immunogenicity.³⁶ Antibodies to NAPs do not result in loss of efficacy and hence are not clinically relevant as antibodies targeting the heavy or light chains.³⁸ Many factors concerning the structure of the BoNT, such as the ratio of active to inactive core neurotoxin, can affect its immunogenicity. Inactive protein refers to the 150 kD precursor protein formed prior to further protease cleaving into 100 kD heavy chain and 50 kD light chain. Although inactive, this 150 kD protein bears the same epitopes as the heavy and the light chain and remains immunogenic.³⁹ As a consequence, products with a higher ratio of inactive to active toxin are more prone to generating antibodies and have a lower specific biologic activity, which denotes the ratio of biologic activity to antigenic toxin.⁴⁰ Patients' characteristics may also affect the immunogenicity, as patients may already have antibodies related to prior botulism or vaccinations. Though there is no animal or human data support, some have theorized that tetanus vaccinations may contribute BoNT NAb formation, as tetanus toxin has a greater than 50% homology in amino acids to BoNT-A and BoNT-B.²⁷

Antibody Detection

Various laboratory assays have been used to detect antibodies in patients with possible immune resistance. Structural assays such as ELISA and immunoprecipitation assays (IPA)⁴¹ are sensitive in the detection of BoNT antibodies however, they are unable to discriminate between neutralizing and non-neutralizing antibodies. Bioassays such as mouse protection assay or mouse hemidiaphragm assay utilize animals to identify neutralizing antibodies that impact clinical efficacy. There are other methods like the western blot assay, synaptosome inhibition assay, sternocleidomastoid test, electrical stimulation of the injected muscle and clinical test such as

Unilateral brow injection (UBI) or Frontalis antibody test (FTAT). UBI test consists of injecting a standard amount of BoNT in the right (by convention) medial eyebrow.¹⁹ FTAT involves similar BoNT injections used by some investigators in the past for injections in the frontalis muscle and subsequent assessment of asymmetry of forehead wrinkling on eyebrow elevation.⁴²

The possibility of neutralizing antibodies in secondary treatment failure is real and one such case has been discussed when a patient stopped responding to the toxin after series of treatments over a period of 3-years.

CASE REPORT

A 52-year-old female patient who is a professional theatre artist, came in seeking treatment for facial rhytids, after a detailed facial analysis and an insight into her professional requirements of need for expressions on stage; a treatment plan was charted for her. She did not desire any treatment for glabellar rhytids but expressed the need for treatment for lateral canthal rhytids. She had been under treatment for more than three years. She had responded to multiple treatments done during the year 2017 and 2018. The patient complained of no response following treatment in the year 2019, prompting an investigation in August 2019, when a couple of my patients stopped taking the medication due to lack of results. The same month, a final treatment was offered to corroborate her complaint, and to my astonishment, there was no response to the BoNT-A treatment two weeks after injection. In August 2019 with patients consent I sent the blood sample for serology testing for neutralizing antibodies to Toxogen GmbH laboratory in Hannover Germany, we received the results after about one month which was positive (Figures 1 and 2).

Timeline	Preparation	Indication and Dosage	Dosage	Frequency	No of Injection Points	Duration of Effect
2017	Botulinum toxin type A	Lateral canthal lines	9 IU each side	Every 3/4-months	3	3-months
2018	Botulinum toxin type A	Lateral canthal lines	12 IU each side	Every 3/4-months	6	3-months
2019	Botulinum toxin type A	Lateral canthal lines	12 IU each side	Two times followed by serum test	6	None

Figure 1. Before - 10th August 2019



Figure 2. After- 26th August 2019



DISCUSSION

All botulinum toxins are capable of inducing the neutralizing antibodies following repeated injections.²⁶ Antibodies blocking the pharmacological effect of the botulinum neurotoxin are termed as neutralizing antibodies⁴³ non-neutralizing antibodies do not influence the therapeutic effect, but increase the foreign protein load and hence increase the immunogenic risk of forming neutralizing antibodies.¹⁴ Aesthetic indications require lower doses of botulinum toxin preparations however, repeated treatments are required for a sustained outcome, which puts the patients at risk for immunologic reactions with possible formation of neutralizing antibodies and secondary treatment failure. Several papers have reported neutralizing antibodies in this population.⁴⁴⁻⁴⁷ Information concerning antibody formation relates to the therapeutic use mostly. There is no published data on the prevalence of non-response in the aesthetic field however, with the indications and duration of treatment increase; the reports of patients not responding after an initial response will also be increasingly reported. The prevalence of patients developing neutralizing antibodies after long-term treatment of botulinum toxin type A seem to depend on the condition to be treated and the dose given i.e., higher the dose higher the risk, the global incidence varies from 0.3-6% according to the literature.^{16,17,19,20,48,49}

CONCLUSION

In aesthetics practice the treatments repetition with botulinum toxin type A, along with dose requirement is of importance to be able to observe the patient's response with time. This case report concludes that development of neutralizing antibodies is a possibility even with low dose use of botulinum toxin type A used in aesthetic practice and may result in secondary treatment failure. This is probably the first such case reported from Mumbai, India.

CONSENT

The authors have received written informed consent from the patient.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

- Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. *Toxicon*. 2011; 57: 555-565. doi: 10.1016/j.toxicon.2010.12.019
- Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: A help or a hindrance? *Biologics*. 2010; 4: 325-332. doi: 10.2147/BTT.S14902
- Kukreja RV, Singh BR. Comparative role of neurotoxin associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex type A and E. *Biochemistry*. 2007; 46: 1416-14324. doi: 10.1021/bi701564f
- Dong M, Yeh F, Tepp WH, et al. SV2 Is the protein receptor for botulinum neurotoxin A. *Science*. 2006; 312: 592-596. doi: 10.1126/science.1123654
- Pirrazini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. *Pharmacol. Rev*. 2017; 69: 200-235. doi: 10.1124/pr.116.012658
- Dressler D, Bigalke H. Immunological aspects of botulinum toxin therapy. *Expert Rev Neurother*. 2017; 17: 487-494. doi: 10.1080/14737175.2017.1262258
- Ojo OO, Fernandez HH. Is it time for flexibility in Botulinum inter-injection intervals? *Toxicon*. 2015; 107: 72-76. doi: 10.1016/j.toxicon.2015.09.037
- Sethi KD, Rodriguez R, Olayinka B. Satisfaction with Botulinum toxin treatment: A cross sectional survey of patients with cervical dystonia. *J. Med. Econ*. 2012; 15: 419-423. doi: 10.3111/13696998.2011.653726
- Evidente VGH, Fernandez HH, LeDoux MS, et al. A randomised, double blind study of repeated Incobotulinumtoxin A(Xeonim®)in cervical dystonia. *J Neural Transm (Vienna)*. 2013; 120: 1699-1707. doi: 10.1007/s00702-013-1048-3
- Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, Fernandez HH, Xeomin US Blepharospasm study group. Sustained efficacy and safety of repeated Incobotulinumtoxin A (Xeomin®) injections in blepharospasm. *J Neural Transm (Vienna)*. 2013; 120: 1345-1353. doi: 10.1007/s00702-013-0998-9
- Kukreja R, Chang TW, Cai S, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. *Toxicon*. 2009; 53: 616-624. doi: 10.1016/j.toxicon.2009.01.017
- Torji Y, Goto Y, Nakahira S, Kozaki S, Ginnaga A. Comparison of the immunogenicity of botulinum type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies. *Toxicon*. 2014; 77: 114-120. doi: 10.1016/j.toxin.2013.11.006
- Dressler D, Wohlfabrt K, Rogge E, Wiest L, Bigalke H. Antibody induced failure of botulinum toxin a therapy in cosmetic indications. *Dermatol Surg*. 2010; 36 (suppl 4): 2182-2187. doi: 10.1111/j.1524-4725.2010.01710.x
- Dressler D, Pan L, Adib Saberi F. Antibody induced failure of toxin therapy: Re-start with low antigenicity drugs offers a new treatment opportunity. *J Neural Transm (Vienna)*. 2018; 125: 1481-1486. doi: 10.1007/s00702-018-1911-3
- Stengel G, Bee EK. Antibody induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines. *Clin Interv Aging*. 2011; 6: 281-284. doi: 10.2147/

CIA. S18997

16. Shulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum toxin type a in urology: Antibodies as a cause of therapy failure. *Int J Urol.* 2008; 15: 407-415: discussion 415. doi: [10.1111/j.1442-2042.2008.02016x](https://doi.org/10.1111/j.1442-2042.2008.02016x)
17. Yablon SA, Brashear A, Gordon MF, Elovic EP. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of post stroke spasticity: A pooled data analysis of three clinical trials. *Clin Ther.* 2007; 29: 683-690. doi: [10.1016/j.clinthera.2007.04.015](https://doi.org/10.1016/j.clinthera.2007.04.015)
18. Yablon S. The development of toxin neutralizing antibodies with botulinum toxin type A (botulinum toxin type A) treatment. *Neurotox Res.* 2006; 9: 238.
19. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, CD-017 BoNTA Study Group. Long term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. *Mov Disord.* 2008; 23: 1353-1360. doi: [10.1002/mds.22157](https://doi.org/10.1002/mds.22157)
20. Muller K, Mix E, Adib Saberi FA, Dressler D, Benecke R. Prevalence of neutralizing antibodies in patients treated with botulinum toxin type A for spasticity. *J Neural Transm (Vienna).* 2009; 116: 579-585. doi: [10.1007/s00702-009.0223-z](https://doi.org/10.1007/s00702-009.0223-z)
21. Dressler D. Pharmacological aspects of therapeutic botulinum toxin preparations. *Nervenarzt.* 2006; 77: 912-921. doi: [10.1007/s00115-006-2090-2](https://doi.org/10.1007/s00115-006-2090-2)
22. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. *Neurology.* 2003; 60: 1186-1188. doi: [10.1212/01.wnl.0000055087.96356bb](https://doi.org/10.1212/01.wnl.0000055087.96356bb)
23. Torres S, Hamilton M, Sanches E, Starovatova P, Gubanova E, Reshetnikova T. Neutralizing antibodies to botulinum toxin type A in aesthetic medicine: Five case reports. *Clin Cosmet Investig Dermatol.* 2014; 7: 11-17. doi: [10.2147/CCID.S51938](https://doi.org/10.2147/CCID.S51938)
24. Dashtipour K, Pedouim F. Botulinum toxin: Preparations for clinical use, immunogenicity, side effects, and safety profile. *Semin Neurol.* 2016; 36: 29-33. doi: [10.1055/s-0035-1571213](https://doi.org/10.1055/s-0035-1571213)
25. Samizadeh S, De Boule K. Botulinum neurotoxin formulations: Overcoming the confusion. *Clin Cosmet Investig Dermatol.* 2018; 11: 273-287. doi: [10.2147/CCID.S156851](https://doi.org/10.2147/CCID.S156851)
26. Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: Neutralizing and non neutralizing antibodies- therapeutic consequences. *Exp Neurol.* 1997; 147: 96-102. doi: [10.1006/exnr.1997.6580](https://doi.org/10.1006/exnr.1997.6580)
27. Nauman M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. *J Neural Transm (Vienna).* 2013; 120: 275-290. doi: [10.1007/s00702-012-0893-9](https://doi.org/10.1007/s00702-012-0893-9)
28. Hsiung GYR, Das SK, Ranawaya R, Lafontain AL, Suchow-ersky O. Long term efficacy of botulinum toxin A in treatment of various movement disorders over a 10 year period. *Mov Disord.* 2002; 17: 1288-1293. doi: [10.1002/mds.10252](https://doi.org/10.1002/mds.10252)
29. Ramirez-Castaneda J, Jankovic J. Long term efficacy and safety of botulinum toxin injections in Dystonia. *Toxins (Basel).* 2013; 5: 249-266. doi: [10.3390/toxins5020249](https://doi.org/10.3390/toxins5020249)
30. Jinnah HA, Goodman E, Rosen AR, Evatt M, Freeman A, Factor S. Botulinum toxin treatment failures in cervical dystonia: Causes management and outcomes. *J Neurol.* 2016; 263: 1188-1194. doi: [10.1007/s00415-016-8136-x](https://doi.org/10.1007/s00415-016-8136-x)
31. Fabbri M, Leodori G, Fernandes RM, et al. Neutralizing antibody and botulinum toxin therapy: Systematic review and meta-analysis. *Neurotox Res.* 2016; 29: 105-117. doi: [10.1007/s12640-015-9565-5](https://doi.org/10.1007/s12640-015-9565-5)
32. Oshima M, Deitiker P, Jankovic J, Attasi MZ. The regions on the light chain of botulinum toxin type A recognised by T cells from toxin related cervical dystonia patients. The complete human T cell recognition map of the toxin molecule. *Immunol Investig.* 2018; 47: 18-39. doi: [10.1080/08820139.2017.1368544](https://doi.org/10.1080/08820139.2017.1368544)
33. Dolimbek BZ, Steward LE, Aoki KR, Attasi MZ. Location of the synaptosome binding regions on botulinum toxin B. *Biochemistry.* 2012; 51: 316-328. doi: [10.1021/bi201322c](https://doi.org/10.1021/bi201322c)
34. Sankhla C, jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. *Mov Disord.* 1998; 13: 150-154. doi: [10.1002/mds.870130128](https://doi.org/10.1002/mds.870130128)
35. Dressler D, Pan L, Adib Saberi F. Antibody induced failure of botulinum toxin therapy: Re-start with low antigenicity drugs offers a new treatment opportunity. *J Neural Transm (Vienna).* 2018; 125: 1481-1486. doi: [10.1007/s00702-018-1911-3](https://doi.org/10.1007/s00702-018-1911-3)
36. Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H. Antibody induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses? *Eur Neurol.* 2002; 47: 118-121. doi: [10.1159/000047963](https://doi.org/10.1159/000047963)
37. Joshi SG, Elias M, Singh A, et al. Modulation of botulinum toxin induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments. *Neuroscience.* 2011; 179: 208-222. doi: [10.1016/j.neuroscience.2011.01.033](https://doi.org/10.1016/j.neuroscience.2011.01.033)
38. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: A comparative review of biochemical and pharmacological actions. *Eur J Neurol.* 2001; 8 (Suppl.5): 21-29. doi: [10.1046/j.1468-1331.2001.00035.x](https://doi.org/10.1046/j.1468-1331.2001.00035.x)
39. Dressler D, Hallet M. Immunological aspects of botox, dysport and myobloc/neurobloc. *Eur J Neurol.* 2006; 13 (Suppl. 1): 11-15. doi: [10.1111/j.1468-1331.2006.01439.x](https://doi.org/10.1111/j.1468-1331.2006.01439.x)

40. Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. *J Neurol Neurosurg Psychiatry*. 1999; 66: 612-616. doi: [10.1136/jnnp.66.5.612](https://doi.org/10.1136/jnnp.66.5.612)
41. Hanna PA, Jankovic J. Mouse bioassay versus western blot assay for botulinum toxin antibodies: Correlation with clinical response. *Neurology*. 1998; 50(6): 1624-1629. doi: [10.1212/wnl.50.6.1624](https://doi.org/10.1212/wnl.50.6.1624)
42. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. *Mov Disord*. 2004; 19 suppl 8: S92-S100. doi: [10.1002/mds.20022](https://doi.org/10.1002/mds.20022)
43. Borodic G. Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides. *Ophthal Plast Reconsr*. 2006; 22: 239-240. doi: [10.1097/01.iop.0000217703.80859.a3](https://doi.org/10.1097/01.iop.0000217703.80859.a3)
44. Lee SK. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. *Dermatol Surg*. 2007; 33 (1 Spec No): S105-S110. doi: [10.1111/j.1524-4725.2006.32340.x](https://doi.org/10.1111/j.1524-4725.2006.32340.x)
45. Dressler D, Wohlfahrt K, Mever-Rogg E, Bigalke H. Antibody-induced failure of botulinum toxin type A therapy in cosmetic indications. *Dermatol Surg*. 2010; 36 Suppl 4: 2182-2187. doi: [10.1111/j.1524-4725.2010.01710.x](https://doi.org/10.1111/j.1524-4725.2010.01710.x)
46. Stengel G, Bee EK. Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines. *Clin Interv Aging*. 2011; 6: 281-284. doi: [10.2147/CIA.S18997](https://doi.org/10.2147/CIA.S18997)
47. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Delger R, Kollewe K. A long term follow up of botulinum toxin A in cervical dystonia. *Neurol Res*. 2009; 31: 463-466. doi: [10.1179/174313209X405137](https://doi.org/10.1179/174313209X405137)
48. Nauman M, Carruthers A, Carruthers J, et al. Meta analysis of neutralizing antibody conversion with onabotulinum toxin A (BO-TOX®) across multiple indications. *Mov Disord*. 2010; 25: 2211-2218. doi: [10.1002/mds.23254](https://doi.org/10.1002/mds.23254)
49. Frevert J. Pharmacological, biological and clinical properties of botulinum neurotoxin type A products. *Drugs R D*. 2015; 15(1): 1-9. doi: [10.1007/s40268-014-0077-1](https://doi.org/10.1007/s40268-014-0077-1)